Compare SHIP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHIP | AGEN |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.9M | 274.8M |
| IPO Year | 2008 | 1999 |
| Metric | SHIP | AGEN |
|---|---|---|
| Price | $17.63 | $7.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $23.25 | ★ $26.33 |
| AVG Volume (30 Days) | 405.8K | ★ 1.1M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $27.31 | $9.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.34 | ★ $7.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $7.66 | $2.71 |
| 52 Week High | $19.22 | $10.19 |
| Indicator | SHIP | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 44.90 |
| Support Level | $15.92 | $3.04 |
| Resistance Level | $19.20 | $8.64 |
| Average True Range (ATR) | 0.61 | 0.69 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 49.02 | 8.64 |
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through a modern fleet of Capesize vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Blueship, Meiship, Kaizenship, Iconship, Titanship, Flagship, Paroship, Worldship, Hellasship, Partnership, Championship, Patriotship, Dukeship, Honorship, Fellowship, Knightship, Lordship, Premiership, Squireship, and Friendship.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.